Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

NCT07076836 · tracked via the Priya Life Science China tracker

Sponsor

West China Hospital

Phase

Not applicable

Started

2026-08-31

Last updated

2026-09-02

Condition(s) studied

Lung Cancer (NSCLC)Immune Checkpoint BlockadeElectroacupuncture

Investigational drug(s) / intervention(s)

Acupuncturesham acupuncture

Acupuncture: The electroacupuncture parameters were set as follows: frequency at 10 Hz, current intensity at 0.5 mA, pulse width at 50 μs, and each session lasted 30 minutes. On the first day of chemotherapy, electroacupuncture was administered 1-2 hours prior to chemotherapy initiation. From Day 2 to the final day of chemotherapy, electroacupuncture sessions were conducted daily between 2:00 PM and 4:00 PM.

sham acupuncture: The sham electroacupuncture group referenced the same acupoints as the electroacupuncture group, but the false acupoint shallow needling method and false electrode method are used, and the treatment time and course are the same as the electroacupuncture group.

Study summary

This study aims to investigate the potential synergistic effects of acupuncture combined with immune checkpoint inhibitors in cancer therapy. Over the past decade, significant progress in cancer immunotherapy has been driven by breakthroughs in understanding immune checkpoint molecules; however, monotherapy with immune checkpoint inhibitors still faces challenges due to low response rates. As a traditional Chinese medical intervention, acupuncture modulates neuro-immune pathways to achieve remote regulation of organ functions, with particular anti-tumor potential observed at the Zusanli (ST36) acupoint-a site located 2 cm below the knee that can be stimulated via electroacupuncture (EA) to improve gastrointestinal function and alleviate inflammation. Preclinical evidence demonstrates that EA suppresses tumor growth in breast cancer models, reduces levels of pro-inflammatory cytokines such as IL-1β and TNF-α, enhances anti-tumor activity of CD8+ T cells and NK cells, and decreases accumulation of immunosuppressive myeloid-derived suppressor cells (MDSCs). Animal studies show that ST36 EA increases key immunomodulatory factors like serum IFN-γ, IL-2, and IL-17, thereby potentiating the efficacy of anti-tumor drugs. Guided by the traditional TCM principle of "reinforcing healthy qi to consolidate the body's resistance," modern clinical applications of EA combined with specific acupoint regimens (e.g., ST36, Sanyinjiao) have effectively alleviated cancer-related pain, chemotherapy-induced side effects, and fatigue. This study will evaluate the safety and immunosensitization effects of ST36 EA combined with PD-1 inhibitors in non-small cell lung cancer patients, employing 1 mA electroacupuncture for 3 consecutive days to activate immune responses. By leveraging acupuncture-induced immune remodeling, this approach aims to provide a novel integrative medicine strategy to overcome resistance to immunotherapy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Age ≥18 and ≤80 years at the time of written informed consent, of either sex; 2. Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) receiving neoadjuvant immunotherapy; 3. Undergoing standard neoadjuvant treatment with chemotherapy plus immunotherapy 4. ECOG performance status score of 0-2; 5. Life expectancy \>3 months; 6. At least one measurable target lesion per RECIST 1.1 criteria: 7. Tumor lesions with a long axis ≥10 mm on CT scan (slice thickness ≤5 mm); 8. Lymph node lesions with a short axis ≥10 mm on CT scan; 9. Previously irradiated or locally treated lesions may be designated as target lesions if documented tumor progression post-treatment. 10. Adequate major organ function within 14 days prior to randomization, defined by the following laboratory parameters without blood transfusions, growth factors, albumin, or blood products: 11. Hematological tests: Hemoglobin ≥80 g/L; Absolute neutrophil count \>1.5×10⁹/L; Platelet count ≥90×10⁹/L; 12. Biochemical tests: Total bilirubin ≤1.5×ULN (upper limit of normal); ALT/AST ≤2.5×ULN; Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); 13. Coagulation tests: Prothrombin time (PT) and INR ≤1.5×ULN (unless on warfarin anticoagulation); 14. Cardiac evaluation: Left ventricular ejection fraction (LVEF) ≥50% by Doppler echocardiography. 15. Voluntary participation with signed informed consent, good compliance, and willingness of the patient and their family to cooperate with survival follow-up. Exclusion Criteria: 1. Pregnant participants; 2. Post-organ transplant patients; 3. Patients with uncontrolled diabetes mellitus, severe cardiac, central nervous system, psychiatric disorders, or coagulopathy; 4. Patients with severe malnutrition; 5. Patients with implanted cardiac pacemakers; 6. Patients with bleeding disorders; 7. Patients with a history of severe allergies or anaphylaxis; 8. Patients with skin infections, lesions, ulcers, or scars at the ST36 (Zusanli) acupoint site; 9. Patients with metal allergy, severe needle phobia, or intolerance to electroacupuncture therapy.

Primary outcome measure(s)

Neoadjuvant Immunotherapy Conversion Rate — Baseline, After neoadjuvant immunotherapy (2-3 cycle, about 2 months after baseline)

Trial sites (1)

Facility	City	Region	Status
West China Hospital	Chengdu	Sichuan	Recruiting

More West China Hospital trials in China

Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations Recruiting

Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis Starting soon

Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy Recruiting

A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma Recruiting

Other trials for the same condition

Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer Starting soon

Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer Recruiting

Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study Recruiting

Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC Recruiting

Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07076836 on ClinicalTrials.gov ↗ ← All trials in China